In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.

RE, Chen; ES, Winkler; JB, Case; ID, Aziati; TL, Bricker; A, Joshi; TL, Darling; B, Ying; JM, Errico; S, Shrihari; LA, VanBlargan; X, Xie; P, Gilchuk; SJ, Zost; L, Droit; Z, Liu; S, Stumpf; D, Wang; SA, Handley; WB Jr, Stine; PY, Shi; ME, Davis-Gardner; MS, Suthar; MG, Knight; R, Andino; CY, Chiu; AH, Ellebedy; DH, Fremont; SPJ, Whelan; JE Jr, Crowe; L, Purcell; D, Corti; ACM, Boon; MS, Diamond

doi:10.1038/s41586-021-03720-y

Public

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.

Shared by NobleBlocks on Jun 21, 2021 • 12:00 AM UTC

Authors:

Chen RE

Winkler ES

Case JB

Abstract

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-2<sup>1-3</sup>, the in vivo importance of these results remains unc...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!